Ongoing Clinical Trials for Laryngeal Leukoplakia
Currently, there is one ongoing clinical trial investigating new treatment options for laryngeal leukoplakia, a condition characterized by white patches on the vocal cords. This trial is testing antimicrobial medications to determine if they can help reduce or eliminate these patches, potentially improving outcomes for patients affected by this condition.
Clinical trial locations
Study on Fluconazole and Cefalexin Monohydrate for Treating Laryngeal Leukoplakia in Adults
This clinical trial is investigating whether antimicrobial treatment can help patients with laryngeal leukoplakia, a condition where white patches form on the voice box. The study is being conducted in Finland and will test two medications: Diflucan (fluconazole) and Kefexin (cefalexin monohydrate).
Who can participate:
- Adults aged between 18 and 64 years
- Both men and women
- Patients who have been diagnosed with laryngeal leukoplakia
- Individuals who are not part of a vulnerable population requiring special protection
Who cannot participate:
- People outside the age range of 18 to 64 years
- Individuals with medical conditions other than laryngeal leukoplakia
- People who are part of vulnerable populations
What the trial involves:
The main goal of this study is to determine whether antimicrobial medications can help the white patches associated with laryngeal leukoplakia disappear. Participants will take two medications orally: Diflucan 100 mg once daily as a hard capsule, and Kefexin 500 mg twice daily as a film-coated tablet. Some participants may receive a placebo instead of the active medications.
Throughout the study, which can last up to six months, participants will attend regular check-ups to monitor their progress and assess how well the treatment is working. The medications work by targeting microorganisms that may contribute to the development or persistence of the white patches in the larynx.
The study aims to see if these antimicrobial treatments can effectively reduce or eliminate the patches, thereby improving the health and quality of life for those affected. The trial is expected to conclude by December 30, 2029.
Summary
Currently, there is one active clinical trial exploring treatment options for laryngeal leukoplakia. This trial is taking place in Finland and focuses on testing antimicrobial medications, specifically fluconazole and cefalexin monohydrate, to see if they can help eliminate the white patches characteristic of this condition. The study is open to adults aged 18 to 64 and will run for up to six months per participant. This research represents an important step in understanding whether antimicrobial treatment can be an effective approach for managing laryngeal leukoplakia and potentially preventing its progression to more serious complications.
